Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") earlier today, on 9 February 2022, regarding the
commencement of the subscription period in the rights issue (the "Rights
Issue").

Please see the attached notifications of trade for information regarding the
primary insiders' and their close associates' receipt of subscription rights in
the Rights Issue.

For further information about the Company, please contact:

Björn Larsson, CEO of Observe Medical,
Mobile: +46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com

Per Arne Nygård, CFO of Observe Medical,
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

For information about the Rights Issue please contact the Managers:

Carnegie AS, tel.: +47 22 00 93 40
DNB Markets, tel.: +47 23 26 81 01

About Observe Medical

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders bacterial migration that can lead to urinary infections
(SippCoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.